Jagsonpal Change To Account Receivables vs Stock Based Compensation Analysis

JAGSNPHARM

636.65 9.80 1.52%

Jagsonpal Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Jagsonpal Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jagsonpal Pharmaceuticals is a good investment. Please check the relationship between Jagsonpal Pharmaceuticals Change To Account Receivables and its Stock Based Compensation accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jagsonpal Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Change To Account Receivables vs Stock Based Compensation

Change To Account Receivables vs Stock Based Compensation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jagsonpal Pharmaceuticals Change To Account Receivables account and Stock Based Compensation. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Jagsonpal Pharmaceuticals' Change To Account Receivables and Stock Based Compensation is 0.46. Overlapping area represents the amount of variation of Change To Account Receivables that can explain the historical movement of Stock Based Compensation in the same time period over historical financial statements of Jagsonpal Pharmaceuticals Limited, assuming nothing else is changed. The correlation between historical values of Jagsonpal Pharmaceuticals' Change To Account Receivables and Stock Based Compensation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Account Receivables of Jagsonpal Pharmaceuticals Limited are associated (or correlated) with its Stock Based Compensation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Stock Based Compensation has no effect on the direction of Change To Account Receivables i.e., Jagsonpal Pharmaceuticals' Change To Account Receivables and Stock Based Compensation go up and down completely randomly.

Correlation Coefficient

0.46

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Change To Account Receivables

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Most indicators from Jagsonpal Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jagsonpal Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jagsonpal Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

The Jagsonpal Pharmaceuticals' current Selling General Administrative is estimated to increase to about 72.9 M, while Tax Provision is projected to decrease to under 38.7 M.

	2021	2022	2023	2024 (projected)
Interest Expense	2.6M	4.1M	8.1M	7.7M
Depreciation And Amortization	15.3M	11.8M	16.6M	14.6M

Interest Expense Depreciation And Amortization

Jagsonpal Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Accounts Payable	Current Deferred Revenue	Good Will	Other Liab
Total Assets		-0.23	0.34	-0.07	0.91	-0.33	-0.08	0.78	-0.1	-0.37	0.07	0.77	-0.47	0.2	-0.14	-0.78	0.51	-0.06	-0.22	0.9	-0.31	0.17	0.09	-0.31	-0.78	-0.29
Short Long Term Debt Total	-0.23		-0.62	0.55	-0.58	0.87	0.9	-0.44	-0.57	0.61	0.27	-0.49	0.82	-0.08	0.34	0.12	-0.43	-0.2	0.94	-0.47	0.94	-0.07	-0.61	-0.25	0.3	0.72
Other Current Liab	0.34	-0.62		0.11	0.5	-0.42	-0.57	0.47	0.42	-0.31	-0.24	0.4	-0.46	0.05	-0.74	-0.17	0.32	0.05	-0.51	0.4	-0.45	0.05	0.32	0.36	-0.33	-0.55
Total Current Liabilities	-0.07	0.55	0.11		-0.35	0.67	0.34	-0.18	-0.04	0.69	0.18	-0.38	0.49	-0.07	-0.56	0.16	-0.29	-0.32	0.69	-0.41	0.7	-0.05	0.03	-0.07	0.36	0.29
Total Stockholder Equity	0.91	-0.58	0.5	-0.35		-0.63	-0.39	0.79	0.08	-0.59	-0.02	0.82	-0.69	0.16	-0.2	-0.67	0.58	0.03	-0.59	0.96	-0.63	0.12	0.24	-0.18	-0.77	-0.48
Property Plant And Equipment Net	-0.33	0.87	-0.42	0.67	-0.63		0.74	-0.65	-0.42	0.86	0.17	-0.72	0.89	-0.42	0.09	0.22	-0.68	-0.13	0.93	-0.58	0.95	-0.41	-0.46	0.04	0.55	0.79
Net Debt	-0.08	0.9	-0.57	0.34	-0.39	0.74		-0.3	-0.87	0.39	0.36	-0.33	0.78	-0.03	0.41	0.1	-0.39	-0.16	0.75	-0.26	0.8	-0.02	-0.81	-0.39	0.05	0.81
Retained Earnings	0.78	-0.44	0.47	-0.18	0.79	-0.65	-0.3		0.07	-0.65	0.02	0.91	-0.68	0.58	-0.2	-0.64	0.69	-0.09	-0.49	0.76	-0.56	0.56	0.23	-0.38	-0.85	-0.57
Cash	-0.1	-0.57	0.42	-0.04	0.08	-0.42	-0.87	0.07		-0.09	-0.38	0.09	-0.54	-0.03	-0.38	-0.04	0.27	0.11	-0.37	-0.02	-0.45	-0.03	0.79	0.52	0.22	-0.75
Non Current Assets Total	-0.37	0.61	-0.31	0.69	-0.59	0.86	0.39	-0.65	-0.09		-0.08	-0.78	0.68	-0.54	-0.14	0.24	-0.62	-0.17	0.78	-0.66	0.76	-0.52	-0.02	0.07	0.74	0.65
Non Currrent Assets Other	0.07	0.27	-0.24	0.18	-0.02	0.17	0.36	0.02	-0.38	-0.08		-0.04	0.22	0.05	-0.03	0.27	-0.39	-0.24	0.18	0.08	0.22	0.05	-0.16	-0.25	-0.06	0.13
Cash And Short Term Investments	0.77	-0.49	0.4	-0.38	0.82	-0.72	-0.33	0.91	0.09	-0.78	-0.04		-0.78	0.66	-0.01	-0.71	0.79	-0.02	-0.58	0.8	-0.66	0.64	0.15	-0.23	-0.94	-0.61
Net Receivables	-0.47	0.82	-0.46	0.49	-0.69	0.89	0.78	-0.68	-0.54	0.68	0.22	-0.78		-0.43	0.18	0.46	-0.72	0.08	0.8	-0.59	0.89	-0.41	-0.62	-0.02	0.56	0.83
Common Stock Shares Outstanding	0.2	-0.08	0.05	-0.07	0.16	-0.42	-0.03	0.58	-0.03	-0.54	0.05	0.66	-0.43		0.05	-0.29	0.68	-0.15	-0.25	0.14	-0.3	1.0	-0.02	-0.36	-0.61	-0.36
Non Current Liabilities Total	-0.14	0.34	-0.74	-0.56	-0.2	0.09	0.41	-0.2	-0.38	-0.14	-0.03	-0.01	0.18	0.05		-0.13	-0.07	0.23	0.18	-0.04	0.11	0.05	-0.5	-0.09	-0.1	0.29
Inventory	-0.78	0.12	-0.17	0.16	-0.67	0.22	0.1	-0.64	-0.04	0.24	0.27	-0.71	0.46	-0.29	-0.13		-0.55	0.11	0.12	-0.63	0.26	-0.27	-0.02	0.16	0.68	0.21
Other Current Assets	0.51	-0.43	0.32	-0.29	0.58	-0.68	-0.39	0.69	0.27	-0.62	-0.39	0.79	-0.72	0.68	-0.07	-0.55		-0.02	-0.53	0.52	-0.56	0.65	0.2	-0.21	-0.64	-0.61
Other Stockholder Equity	-0.06	-0.2	0.05	-0.32	0.03	-0.13	-0.16	-0.09	0.11	-0.17	-0.24	-0.02	0.08	-0.15	0.23	0.11	-0.02		-0.15	0.08	-0.19	-0.14	-0.05	0.38	-0.01	-0.11
Total Liab	-0.22	0.94	-0.51	0.69	-0.59	0.93	0.75	-0.49	-0.37	0.78	0.18	-0.58	0.8	-0.25	0.18	0.12	-0.53	-0.15		-0.51	0.96	-0.23	-0.39	-0.09	0.44	0.65
Total Current Assets	0.9	-0.47	0.4	-0.41	0.96	-0.58	-0.26	0.76	-0.02	-0.66	0.08	0.8	-0.59	0.14	-0.04	-0.63	0.52	0.08	-0.51		-0.55	0.1	0.08	-0.17	-0.8	-0.45
Short Term Debt	-0.31	0.94	-0.45	0.7	-0.63	0.95	0.8	-0.56	-0.45	0.76	0.22	-0.66	0.89	-0.3	0.11	0.26	-0.56	-0.19	0.96	-0.55		-0.29	-0.51	-0.09	0.5	0.72
Common Stock	0.17	-0.07	0.05	-0.05	0.12	-0.41	-0.02	0.56	-0.03	-0.52	0.05	0.64	-0.41	1.0	0.05	-0.27	0.65	-0.14	-0.23	0.1	-0.29		-0.01	-0.35	-0.58	-0.35
Accounts Payable	0.09	-0.61	0.32	0.03	0.24	-0.46	-0.81	0.23	0.79	-0.02	-0.16	0.15	-0.62	-0.02	-0.5	-0.02	0.2	-0.05	-0.39	0.08	-0.51	-0.01		0.1	0.15	-0.64
Current Deferred Revenue	-0.31	-0.25	0.36	-0.07	-0.18	0.04	-0.39	-0.38	0.52	0.07	-0.25	-0.23	-0.02	-0.36	-0.09	0.16	-0.21	0.38	-0.09	-0.17	-0.09	-0.35	0.1		0.28	-0.28
Good Will	-0.78	0.3	-0.33	0.36	-0.77	0.55	0.05	-0.85	0.22	0.74	-0.06	-0.94	0.56	-0.61	-0.1	0.68	-0.64	-0.01	0.44	-0.8	0.5	-0.58	0.15	0.28		0.36
Other Liab	-0.29	0.72	-0.55	0.29	-0.48	0.79	0.81	-0.57	-0.75	0.65	0.13	-0.61	0.83	-0.36	0.29	0.21	-0.61	-0.11	0.65	-0.45	0.72	-0.35	-0.64	-0.28	0.36

Click cells to compare fundamentals

Jagsonpal Pharmaceuticals Account Relationship Matchups

Jagsonpal Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.5B	1.6B	1.7B	1.9B	2.2B	1.7B
Short Long Term Debt Total	37.9M	46.6M	67.9M	60.0M	89.4M	165.5M
Other Current Liab	155.5M	117.4M	4.6M	183.3M	88.5M	78.7M
Total Current Liabilities	328.3M	404.0M	341.6M	275.7M	191.3M	361.4M
Total Stockholder Equity	1.1B	1.2B	1.3B	1.6B	1.9B	1.2B
Property Plant And Equipment Net	239.6M	233.5M	223.7M	242.8M	93.0M	88.4M
Net Debt	(334.1M)	(518.4M)	(251.4M)	(50.5M)	(38.2M)	(36.3M)
Retained Earnings	476.9M	585.9M	675.2M	945.4M	1.0B	1.1B
Cash	380.7M	586.3M	251.4M	110.5M	127.6M	199.6M
Non Current Assets Total	520.4M	437.3M	576.8M	303.9M	178.2M	169.3M
Non Currrent Assets Other	(353.8M)	38.3M	29.2M	27.2M	38.2M	40.1M
Cash And Short Term Investments	380.7M	618.8M	472.8M	1.1B	1.5B	1.6B
Net Receivables	224.5M	126.6M	155.8M	221.1M	109.5M	104.0M
Liabilities And Stockholders Equity	1.5B	1.6B	1.7B	1.9B	2.2B	1.7B
Non Current Liabilities Total	30.9M	18.8M	34.4M	84.8M	105.5M	87.4M
Inventory	293.3M	297.2M	297.4M	206.8M	150.0M	247.3M
Other Current Assets	274.5M	143.6M	80.6M	41.9M	363.2M	381.4M
Total Liab	359.2M	422.7M	376.0M	360.6M	296.8M	350.2M
Total Current Assets	949.1M	1.2B	1.1B	1.6B	2.0B	1.1B
Accumulated Other Comprehensive Income	(337.4M)	1.1B	496.9M	506.5M	588.7M	618.2M
Short Term Debt	64.0M	67.9M	7.5M	7.5M	13.8M	13.1M
Accounts Payable	117.1M	180.5M	185.5M	78.5M	76.0M	96.0M
Current Deferred Revenue	92.1M	137.5M	(7.5M)	81.4M	12.9M	12.3M
Other Liab	30.9M	18.8M	34.4M	32.4M	29.1M	26.0M
Net Tangible Assets	1.1B	1.2B	1.3B	1.6B	1.8B	1.2B
Other Assets	170.1M	82.9M	147.0M	20.3M	23.4M	22.2M
Property Plant Equipment	239.6M	233.5M	223.7M	242.8M	218.5M	258.8M
Cash And Equivalents	398.1M	589.4M	232.3M	110.5M	127.1M	242.0M
Net Invested Capital	1.2B	1.3B	1.3B	1.6B	1.9B	1.5B
Net Working Capital	620.8M	800.8M	766.2M	1.4B	1.8B	1.1B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Other Information on Investing in Jagsonpal Stock

Balance Sheet is a snapshot of the financial position of Jagsonpal Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Jagsonpal Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Jagsonpal Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Jagsonpal currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jagsonpal Change To Account Receivables vs Stock Based Compensation Analysis

Change To Account Receivables vs Stock Based Compensation

Change To Account Receivables vs Stock Based Compensation Correlation Analysis

Correlation Coefficient

Change To Account Receivables

Stock Based Compensation

Jagsonpal Pharmaceuticals fundamental ratios Correlations

Jagsonpal Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Jagsonpal Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in Jagsonpal Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Shares Outstanding
Total Current Assets	+ 0.96	Total Stockholder Equity
Short Term Debt	+ 0.96	Total Liab
Short Term Debt	+ 0.95	Property Plant And Equipment Net
Total Liab	+ 0.94	Short Long Term Debt Total
Short Term Debt	+ 0.94	Short Long Term Debt Total

Good Will	- 0.94	Cash And Short Term Investments
Cash	- 0.87	Net Debt
Good Will	- 0.85	Retained Earnings
Accounts Payable	- 0.81	Net Debt
Good Will	- 0.8	Total Current Assets
Net Receivables	- 0.78	Cash And Short Term Investments